Data exclusivity—the granting of exclusive rights to commercial companies over clinical and preclinical trial data—could jeopardize efforts to create generic versions of life-saving medicines and harm public health, says Karin Timmermans of the World Health Organization (WHO) in an Essay in PLoS Medicine.>>> Discuss This Story
